Business Overview: CytoSorbents Corporation (Nasdaq: CTSO)

---

Executive Summary

CytoSorbents Corporation is a critical-care medical device company that has commercialized CytoSorb, a single-use, extracorporeal ("outside the body") blood-purification cartridge filled with biocompatible, highly porous polymer beads that adsorb cytokines, toxins, and other harmful middle-molecular-weight substances from a patient's blood during critical illness — functioning, in the company's own framing, more like an artificial liver than an artificial kidney. CE Marked in Europe since 2011 and distributed in more than 70 countries through a mix of direct sales and major partners including Fresenius Medical Care and B. Braun Avitum, CytoSorb has now been used in over 300,000 cumulative treatments, primarily in sepsis, COVID-19 respiratory failure, cardiac surgery, and other critical-illness indications. The device holds a narrow, indication-specific FDA Emergency Use Authorization for critically ill COVID-19 patients but has never received full FDA marketing approval for its core critical-care indications, leaving CytoSorbents largely dependent on European and international revenue.

The company's most important near-term catalyst is DrugSorb-ATR, a related cartridge designed to remove antiplatelet and anticoagulant drugs (initially ticagrelor) from the blood of cardiac surgery patients to reduce perioperative bleeding. After receiving two FDA Breakthrough Device Designations and initially pursuing De Novo marketing authorization, the company disclosed in its fourth-quarter/full-year 2025 results that it is now pursuing a new De Novo application incorporating additional real-world data, following continued interactive discussions with the FDA — an implicit signal that the original submission did not lead to a swift clearance and that U.S. market entry, and the larger revenue opportunity it represents, has been pushed further out.

The single most decision-relevant fact for investors is CytoSorbents's precarious liquidity position relative to its cash burn: full-year 2025 revenue of $37.1 million grew only 4%, and while the net loss narrowed to $8.2 million (from $20.7 million in 2024, a year that included large one-time items), the company ended 2025 with just $6.2 million of unrestricted cash (total liquidity of $7.8 million including restricted cash) against $16.7 million of long-term debt. Management responded with a 10% workforce reduction in the fourth quarter of 2025 and now targets cash-flow breakeven only in the second half of 2026 — meaning further capital raises, additional cost cuts, or accelerated DrugSorb-ATR approval are all likely necessary before the company reaches self-sufficiency, a risk reflected in a market capitalization that has fallen roughly 65% over the trailing year to approximately $23 million.

---

1. Core Business Model & How They Work

CytoSorbents generates revenue by selling single-use polymer-bead adsorption cartridges (CytoSorb and related products) that hospitals use in conjunction with existing continuous renal replacement therapy (CRRT), extracorporeal membrane oxygenation (ECMO), or cardiopulmonary bypass equipment already present in the ICU or operating room. Because the cartridges are disposable and used per-patient, per-treatment, revenue is transactional and scales with device utilization rather than recurring subscription or capital-equipment economics. The company sells directly in select markets (notably a German subsidiary, CytoSorbents Europe GmbH) and relies heavily on distribution partnerships — most importantly with Fresenius Medical Care and B. Braun Avitum — to reach the roughly 70-plus countries where CytoSorb holds regulatory clearance. A large share of the company's historical R&D funding (approximately $42.3 million cumulatively from 2012–2024) has come from U.S. government sources (DARPA, the Army, Air Force, NIH, USSOCOM, and CDMRP), reflecting the technology's origins in battlefield trauma and biodefense applications as much as commercial critical care.

Key Operational Drivers

1. Ex-U.S. Commercial Base, U.S. Regulatory Optionality — nearly all current revenue comes from Europe and other CE Mark/cleared markets; the U.S., the largest addressable critical-care market, remains largely closed pending full FDA approval.
2. DrugSorb-ATR as the Primary U.S. Catalyst — a narrower, better-defined indication (removing ticagrelor/DOACs before cardiac surgery to cut bleeding) with two FDA Breakthrough Device Designations, now pursuing a refiled De Novo application with additional real-world evidence.
3. Partner-Dependent Distribution — reliance on Fresenius, B. Braun, and other partners for scale distribution means CytoSorbents captures less margin per treatment than a fully direct model but gains access to established hospital relationships.
4. Reimbursement-Dependent Adoption — country-specific reimbursement codes (e.g., Germany's OPS 8-821.30, Switzerland's CHOP code) materially affect utilization; Germany's 2025–2029 hospital-system reform introduces both transition risk and potential opportunity in the company's largest market.
5. Thin Liquidity Requiring Near-Term Self-Funding — with only $7.8 million of total liquidity against $16.7 million of debt, continued execution on cost reduction (the Q4 2025 workforce cut) and revenue growth is required to reach the targeted H2 2026 cash-flow breakeven without further dilutive financing.

---

2. Business Segments

CytoSorbents operates as a single reportable segment (critical care and cardiac surgery blood purification devices). The portfolio is best understood by product line and target indication rather than by discrete financial segments.

---

3. Product Portfolio

---

4. Competitive Landscape

CytoSorbents competes in a niche but increasingly contested corner of the medical device market — extracorporeal blood purification and adsorption therapy — where its primary structural disadvantage is that most rivals are business units of far larger, better-capitalized, and more diversified medical device companies that can bundle adsorption cartridges with the CRRT or ECMO capital equipment platforms already installed in hospitals. In the DrugSorb-ATR cardiac-surgery indication, CytoSorbents faces a fundamentally different kind of competition: an investigational reversal-agent drug (bentracimab) and, more pervasively, the entrenched clinical default of simply waiting for antiplatelet/anticoagulant drugs to naturally wash out of a patient's system before surgery — a "do nothing" competitor that is difficult to displace without compelling clinical and health-economic data.

Key Competitors:

• Baxter International (Oxiris cytokine-adsorbing filter, integrated with Baxter's own CRRT platform)
• Toray Industries (PMMA membrane-based adsorption)
• Jafron Biomedical (HA330/HA380 hemoperfusion cartridges, strong presence in Asian markets)
• Various other total plasma exchange (TPE) and hemoperfusion device manufacturers
• SFJ Pharmaceuticals (bentracimab, an investigational reversal agent competing for the DrugSorb-ATR cardiac-surgery bleeding-reduction indication)
• The clinical status quo of natural drug washout, which competes with DrugSorb-ATR for surgeon and hospital adoption absent strong comparative evidence

CytoSorbents's differentiation rests on breadth of clinical use cases, a large accumulated real-world evidence base (300,000+ treatments), and a growing patent/trademark estate, but it lacks the platform-bundling advantage that larger, diversified competitors can offer hospital purchasing systems.

---

5. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• Large accumulated real-world clinical evidence base (300,000+ cumulative treatments across 70+ countries) that newer entrants would take years to replicate.
• Broad intellectual property estate covering the core adsorbent polymer bead technology, production methods, and multiple branded product lines (CytoSorb, DrugSorb, ECOS, VetResQ, HemoDefend, and others).
• Two FDA Breakthrough Device Designations for DrugSorb-ATR, which can accelerate FDA review and signal genuine unmet clinical need.
• Validated by non-dilutive government funding (~$42.3 million from DARPA, NIH, the U.S. Army, Air Force, USSOCOM, and CDMRP from 2012–2024), reflecting third-party technical credibility beyond commercial sales.
• Diversified product portfolio spanning critical care, cardiac surgery, organ preservation, and veterinary applications reduces single-indication dependence.

Strategic Risks & Vulnerabilities

1. Liquidity is thin relative to cash burn — $6.2 million of unrestricted cash ($7.8 million total liquidity) against $16.7 million of long-term debt and an operating loss of $14.7 million in 2025 creates real risk of further dilutive equity raises or covenant pressure before the targeted H2 2026 cash-flow breakeven.
2. No full U.S. marketing approval for the core CytoSorb franchise — the U.S. remains accessible only through a narrow COVID-19 EUA, closing off the world's largest critical-care market to the flagship product indefinitely.
3. DrugSorb-ATR regulatory uncertainty — the need to refile a De Novo application with additional real-world data (rather than a straightforward clearance) pushes out the timeline for the company's most important U.S. growth catalyst and adds execution risk.
4. Reimbursement and market-structure risk in Germany, the company's largest market, where a 2025–2029 hospital-system reform could disrupt existing procedure-code-based reimbursement dynamics.
5. Distribution dependency — reliance on partners such as Fresenius Medical Care and B. Braun Avitum for scale distribution gives those larger partners meaningful bargaining leverage over CytoSorbents's economics and market access.

---

6. Financial Overview

---

7. Summary Conclusion

CytoSorbents has built a genuinely differentiated blood-purification technology platform with a decade-plus of European and international commercial use, a large real-world evidence base, and a broad intellectual property estate — assets that would be difficult and time-consuming for a new entrant to replicate from scratch. Yet the company remains financially fragile: modest single-digit revenue growth, persistent operating losses, and a cash position that covers only a few quarters of operations without further financing or faster-than-planned improvement. The investment case hinges almost entirely on two intertwined outcomes — successfully refiling and clearing the DrugSorb-ATR De Novo application to finally unlock meaningful U.S. revenue, and reaching the targeted second-half-2026 cash-flow breakeven without additional significant dilution. Absent progress on both fronts, CytoSorbents risks remaining a niche, ex-U.S.-dependent device maker whose technology is more proven clinically than it is proven as a sustainably self-funding business.